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OBSERVATIONAL studies indicate that topical application
of ricinoleic acid (RA), the main component of castor
oil, exerts  remarkable analgesic and anti-inflamma-
tory  effects.  Pharmacological  characterization  has
shown similarities between the effects of RA and those
of capsaicin, suggesting a potential interaction of this
drug on sensory neuropeptide-mediated neurogenic
inflammation. The aim of this study was to assess RA
anti-inflammatory activities in comparison with cap-
saicin  in  several  models  of  acute  and  subchronic
inflammation. The acute inflammation was induced by
intradermal injection of carrageenan in the mouse or
by  histamine  in  the  guinea-pig  eyelid.  In  either
experiment, the extent of the oedema thickness was
measured. Subchronic oedema was induced by com-
plete Freund’s adjuvant injection in the ventral right
paw of mice. Tissue substance P (SP) was measured in
the carrageenan experiments by radioimmunoassay
(RIA). It was found that the acute topical application of
RA (0.9mg/mouse) or capsaicin (0.09mg/mouse) sig-
nificantly increased the mouse paw oedema induced
by  carrageenan,  while  an  8-day  repeated  topical
treatment  with  the same doses of both compounds
resulted  in  a  marked  inhibition  of  carrageenan-
induced paw oedema matched by a reduction in SP
tissue levels. Similar effects were found against hista-
mine-induced eyelid oedema in guinea-pigs after acute
or repeated application  of RA or capsaicin.  RA and
capsaicin given for 1Ð3 weeks reduced the established
oedema induced by Freund’s adjuvant, a subchronic
model of inflammation, particularly  if given by  the
intradermal route. Either in mouse paw or in guinea-
pig eyelid, capsaicin but not RA by itself produced a
slight  hyperemia  and  activation  of  a  behavioural
response (e.g. scratching of the eyelids). On the basis
of  the  present  results,  RA  may  be  seen  as  a  new
capsaicin-like, non-pungent anti-inflammatory agent
suitable for peripheral application.
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Introduction
Ricinoleic acid (RA; [R-(Z)]–12-hydroxy–9-octadece-
noic  acid)  is  the  main  component  of  castor  oil,
accounting  for  about  90%  of  the  total.  Preliminary
experiments  in  our  laboratories  indicated  that  RA,
known for its laxative properties,1 could have a pro-
or anti-inflammatory action following acute or repeti-
tive  local  application,  respectively.  These  activities
closely resemble those previously described for cap-
saicin  or  capsaicinoid  analogues  called  vanilloids
(olvanil, resiniferatoxin, scutigeral).2–4 On the other
hand, part of the RA chemical structure has been used
as a basis for the development of novel capsaicin-like
compounds.5 The cloning of the vanilloid receptor/
ion channel, termed VR1 is very recent6 and it has
been shown that VR1 is activated by capsaicin and a
number of other capsaicin-like drugs (vanilloid recep-
tor agonists). Vanilloids specifically  act through the
activation and then the desensitization of a subset of
primary  afferent  nerves  involved  in  the  genesis  of
neurogenic inflammation.7 Notably their  acute  pro-
inflammatory effect is due to the stimulation of the
release  of  sensory  neuropeptides  from  peripheral
axons of these nerves. In a subsequent phase there is a
desensitization of these fibres and, if the dose and the
duration of exposure to the agonists are appropriate,
a  depletion  of  the  neuropeptide  content  of  these
nerves occurs.8 Desensitization and/or neuropeptide
depletion  determines  an  anti-inflammatory  effect
blocking  the induction of neurogenic inflammation
by endogenous or exogenous inflammatory stimuli.7
ISSN 0962-9351 print/ISSN 1466-1861 online/00/050223-06 © 2000 Taylor & Francis Ltd 223
DOI: 10.1080/09629350020025737
Research Paper
Mediators of Inflammation, 9, 223–228 (2000)Noteworthy is the fact that we found  that RA is
devoid of the pungent properties typical of capsaicin
and  that  it  does  not  exert  any  hyperalgesic  effect
towards heat and chemical nociceptive stimuli (Vieira
et al., submitted – ref. 9). These similarities and the
differences (lack of pungent properties) with capsai-
cin render RA a promising analgesic and anti-inflam-
matory  agent  via  its  local  application.  Long-term
topical capsaicin application in rats has been shown
to produce a reversible impairment of  the primary
afferent fibres in the skin.10
In view of the above, we have assessed the effect of
acute  or  repetitive  RA  topical  treatment  in  several
models of both acute and subchronic inflammation.
Materials and methods
Animals
Male albino Dunkin–Hartley guinea-pigs (250–350g)
from Charles River (Calco, Italy) and male Swiss mice
(20–25g)  from  Harlan  Nossan  (Correzzana,  Milan,
Italy) were used. The animals were fed with a standard
diet  and  water  ad  libitum. The  experiments  were
performed in respect of the Principles of Laboratory
Animal  Care (NIH  publication  no.  85–23,  revised
1985)  and  in  accordance  with  the  Italian  Health
Ministry  guidelines  for  the  care and  use  of  experi-
mental animals.
Oedema induction in the paw of mice
Paw  oedema  was  induced  by  intradermal  (i.d.)
injection  in  the  right  paw  of  300mg/0.04ml  of
carrageenan. The thickness of the paw was measured
inmm using a micro-calibrator. In acute experiments,
the paw thickness was measured before and 1, 2, 3, 4,
5 and 6h after the carrageenan injection. In chronic
experiments, the progression of oedema was assessed
on the first day and the eighth day each hour during
the 6-h period following the first or second carragee-
nan injection, respectively. Single or repeated (8 days)
topical  applications  of  vehicle  (peanut  oil),  RA
(0.9mg/mouse)  or  capsaicin  (0.09mg/mouse),  at
doses  chosen  in  preliminary  experiments,  were
applied on the ventral surface of the right paw. The
first and the last application were made 30min before
the injection of carrageenan.
In other experiments, the repeated topical applica-
tion  (8  days)  of  vehicle  (peanut  oil),  RA  (0.9mg/
mouse) or capsaicin (0.09mg/mouse) or the repeated
(4  days)  i.d.  administration  of  RA  potassium  salt
(0.03mg/mouse)  or capsaicin (0.003mg/mouse)  on
the ventral surface of the right paw was tested in the
presence  of  complete  Freund’s  adjuvant  (30ml),
injected in  the hind-paw on the first  day. The paw
volume was monitored once a week for 3 weeks as
described above.
Eyelid oedema induction in guinea-pigs
Eyelid  oedema  was  induced  by  i.d.  injection  of
10mg/0.1ml of histamine in the right superior eyelid
of animals under a short anaesthesia by diethyl ether.
The thickness of the eyelid was measured inmm using
ophthalmic  micro-callipers  (Dixey,  UK).  In  acute
experiments,  the  eyelid  thickness  was  measured
before and 1, 2, 3, 4, 5 and 6h after the histamine
injection or maximal applicable doses of RA (100mg/
guinea-pig) and capsaicin (10mg/guinea-pig).
In  subchronic  experiments,  the  animals  were
treated topically for 8 or 22 days with vehicle (peanut
oil),  RA  (0.9mg/guinea-pig)  or  capsaicin  (0.09mg/
guinea-pig), and the progression of the oedema was
assessed on the first day during 6h following the first
histamine injection and then the eighth and the 22nd
day  each  hour  for  a  6-h  period  after  the  second
injection of histamine.
Radioimmunoassay (RIA)
For the tissue peptide measurements, the paws were
rapidly  removed  and  weighed.  The  samples  were
extracted with  3ml  of  2N  acetic acid at  95°C  for
15min. They were then homogenized and centrifuged
at 10000g for 30min at 4°C, the supernatants were
freeze-dried and stored at –20°C until their content of
substance P-like immunoreactivity (SP-LI) was deter-
mined by RIA. Lyophilized samples were reconstituted
in  10ml  of  50 mM  phosphate  buffer  (pH  7.4),
containing 0.3%  bovine serum  albumin  and 10 mM
ethylene  diamine  tetraacetic acid  (EDTA). The  RIA
assay for SP-LI was based on scintillation proximity
assay  technology,  as  previously  described.11 The
incubation mixture was composed of 100ml  of the
reconstituted  sample  (diluted  1:30),  100ml  of
125I-labelled tracer (about 6000cpm), 100ml of diluted
antiserum (1:100000 for SP) and 50ml of scintillation
proximity assay protein A reagent. After an overnight
incubation  at  room  temperature  under  gentle  agi-
tation, the samples were counted in a b-scintillation
counter (2200CA, Canberra-Packard, USA).
Chemicals
RA (99%  pure;  Sigma)  was diluted with  peanut  oil
(Sigma);  its  soluble  potassium  salt  (MEN  11938  or
potassium [R-(Z)]–12-hydroxy–9-octadecenoate from
Chemistry  Department,  Menarini  Ricerche  spa.,
Pomezia, Italy) was used for i.d. treatment dissolved in
saline. Capsaicin (Serva) was dissolved in 10% etha-
nol,  10%  tween  80  and  80%  saline  solution  and
applied locally in peanut oil. Histamine (Sigma) was
dissolved in  saline,  carrageenan (type  II,  Sigma)  in
sterile phosphate buffer solution (PBS; Sigma). Com-
plete Freund’s adjuvant was purchased from Sigma.
[125I]-  Bolton  Hunter  SP  and  scintillation  proximity
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rabbit anti-SP serum (RAS 7451, cross-reactivity < 5%
with SP 7–11, < 0.01% with neurokinin A (NKA) was
from Peninsula Laboratories.
Statistical analysis
The data are expressed as means ± standard error of the
mean  (SEM).  The  statistical  significance  between
groups was assessed using one-way analysis of variance
followed by Bonferroni’s test. The Mann–Whitney U
test was used for the  “in vitro” experiments.
Results
Effects of acute and subchronic topical
treatment with RA and capsaicin on
carrageenan-induced paw oedema in mice
As  shown  in  Fig.  1,  paw  oedema  induced  by
carrageenan was markedly increased by  the topical
application  of  RA  (0.9mg/mouse)  or  capsaicin
(0.09mg/mouse). The enhancement by RA or capsai-
cin of the carrageenan-induced oedema reached its
maximum between the second and fourth hours and
then  decreased  over  time,  but  still  remained  sig-
nificant  at  the  sixth  hour  as  compared  with  the
vehicle-treated  paws  (Fig.  1).  No  enhancement  of
carrageenan-induced oedema was detected with the
vehicle (n = 5) or with a solution at the same pH of
100mg  of  RA  (n =  5).  Topical  administration  of
vehicle,  RA  up  to  10mg/10ml  or  capsaicin  up  to
1mg/10ml did not produce per se any oedema in the
paws of the mice.
The treatment with RA (0.9mg/mouse) for 8 days
did  not  result  per  se in  any  oedematous effect  or
hyperemic reaction. Conversely, during the first days
of treatment, capsaicin (0.09mg/mouse) produced a
slight  hyperemic  reaction  that  disappeared  within
1–2h from treatment. On the eighth day, the carragee-
nan-induced oedema was virtually abolished in RA or
capsaicin pre-treated animals (Fig. 2). Thus, the mice
were unable to produce any oedema in response to
carrageenan.
Effect of topical and i.d. treatment with RA or
capsaicin on Freund’s adjuvant-induced paw
oedema in mice
The intraplantar injection of Freund’s adjuvant in one
of the hind-paws leads to localized, unilateral inflam-
mation. As shown in Table 1, the paw oedema induced
by Freund’s adjuvant peaked at the first 2 weeks after
the  induction and  then declined. Topical  treatment
with  RA  for  8  days  was  effective  in  reducing  the
oedema formation at 1 week observation time. On the
second and third weeks after the oedema induction,
RA did not affect the increase in thickness of the paws
as compared with the vehicle-treated group. Capsai-
cin  in  the  applied  dose  did  not  induce  significant
inhibition in the oedema evoked by Freund’s adjuvant
(Table 1).
Conversely, the i.d. administration of the potassium
salt of RA (MEN 11938) was able to exert a marked
anti-inflammatory effect that lasted for 3 weeks (Table
1). The values of reduction in oedema formation were
68, 67 and 85% of control at 1, 2 and 3 weeks after
Freund’s  adjuvant  injection.  Similarly,  i.d.  capsaicin
significantly  affected  oedema  formation,  the  sig-
nificance of the effect lasting only for 2 weeks; the
oedema was reduced by 50, 57 and 51% at 1, 2 and 3
weeks after its induction (Table 1). The i.d. injection
of capsaicin (0.003mg/mouse), but not RA (0.03mg/
mouse),  produced nociceptive reactions during the
first 2–3 days of treatment.
Anti-inflammatory activity of ricinoleic acid
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FIG. 1. Effects of vehicle, ricinoleic acid (RA, 0.9mg/mouse)
or capsaicin (Cps, 0.09mg/mouse) on carrageenan-induced
paw oedema expressed inmm. Ricinoleic acid, capsaicin and
the vehicle were applied topically 30min before carrageenan
injection. Data are mean ± standard error (SE). n = 5–8 for
each group. **p < 0.01; ***p < 0.001 versus vehicle group.
FIG. 2. Carrageenan-induced oedema of mouse paw. Effects
of 8-day treatment with ricinoleic acid (RA, 0.9mg/mouse) or
capsaicin (Cps, 0.09mg/mouse). Data are mean ± standard
error (SE). n = 5–8 for each group. **p < 0.01; ***p < 0.001
versus vehicle group.Effect of topical application of RA or capsaicin
on guinea-pig eyelid
The topical administration of capsaicin resulted in a
local  hyperemic  response  and  activation  of  behav-
ioural defensive responses including scratching of the
eyelid. Neither hyperemia nor aversive behaviour was
observed  following  RA  topical  treatment.  A  slight
eyelid oedema with the peak at 2h following applica-
tion with high doses of RA (100mg/guinea-pig, 0.23 ±
0.01mm)  or  capsaicin  (10mg/guinea-pig,  0.35  ±
0.005mm) alone was observed.
Effects of acute and subchronic topical
treatment with RA and capsaicin on eyelid
oedema induced by histamine in guinea-pig
The injection of histamine in the right eyelid rapidly
induced  an  oedema  that  reached  the  maximum
thickness at the first hour (Fig. 3). During i.d. injection,
the animals showed aversive response behaviour, but
no  scratching  response  on  the  eyelid  was  usually
observed.  As  shown  in  Fig.  3,  the  oedema  was
increased by the topical application of RA (0.9mg/
guinea-pig) and capsaicin (0.09mg/guinea-pig).
The topical application of RA (0.9mg/guinea-pig)
for 8 days did not result per se in any oedematous
effect  or  hyperemic  reaction.  Instead,  capsaicin
(0.09mg/guinea-pig) produced hyperemic and pain-
ful  reactions that disappeared 1–2h after the treat-
ment.  The  intensity  of  these  responses  gradually
decreased  starting  from  2–3  days  and  was  almost
abolished at the end of the treatment. As shown in Fig.
4,  the  eyelid  oedema  induced  by  histamine  was
markedly reduced after 8  days of  topical treatment
with  RA (0.9mg/guinea-pig)  or  capsaicin (0.09mg/
guinea-pig). A similar profile of oedema reduction was
also found after 3 weeks of topical treatment with RA
(0.9mg/guinea-pig)  or  capsaicin  (0.09mg/guinea-
pig),  the values of eyelid oedema at the peak (first
hour)  being:  1.37  ±  0.06,  0.70  ±  0.05  and  0.85  ±
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Table 1. Paw oedema induced by Freund’s adjuvant in mice. Animals were treated by local application of ricinoleic acid (RA;
900mg/mouse) or capsaicin (90mg/mouse) for 8 days or intradermally administered for 4 days with MEN 11938 (30mg/mouse),
the potassium salt of RA, or capsaicin (3mg/mouse). The paw oedema was measured once a week after the injection of Freund’s
adjuvant
First week Second week Third week
Local application for 8 days
Vehicle 1.39 ± 0.10 0.79 ± 0.05 0.60 ± 0.10
RA (900mg/mouse) 0.82 ± 0.10** 0.61 ± 0.13 0.40 ± 0.07
Capsaicin (90mg/mouse) 0.87 ± 0.13 0.70 ± 0.08 0.48 ± 0.09
Intradermal treatment for 4 days
Vehicle 1.19 ± 0.09 1.20 ± 0.12 0.63 ± 0.10
MEN 11938 (30mg/mouse) 0.38 ± 0.10** 0.40 ± 0.13** 0.09 ± 0.13*
Capsaicin (3mg/mouse) 0.59 ± 0.09** 0.51 ± 0.08** 0.31 ± 0.15
Data are mean ± standard error (SE). n = 8–10 for each group. *p < 0.05; **p < 0.01 versus respective vehicle group.
FIG.  3.  Histamine-induced  oedema  of  guinea-pig  eyelid.
Effect of vehicle, ricinoleic acid (RA, 0.9mg/guinea-pig) and
capsaicin (Cps, 0.09mg/guinea-pig). Ricinoleic acid, capsai-
cin  and  the  vehicle  were  administered  topically  30min
before histamine injection. Data are mean ± standard error
(SE).  n =  5–8  for  each  group.  *p <  0.05;  **p <  0.01;
***p < 0.001 versus vehicle group.
FIG.  4.  Histamine-induced  oedema  of  guinea-pig  eyelid.
Effect  of  8-day treatment  with ricinoleic  acid  (RA,  0.9mg/
guinea-pig) or capsaicin (Cps, 0.09mg/guinea-pig). Data are
mean ± standard error (SE). n = 5–8 for each group. *p < 0.05;
**p < 0.01; ***p < 0.001 versus vehicle group.0.05mm  for  vehicle-,  RA-  and  capsaicin-treated
groups, respectively.
Effect of repeated treatment of RA and
capsaicin on mouse paw SP levels
The levels of  SP were not different  in carrageenan-
inflamed  and  non-inflamed  paws  (1.30  ±  0.28  and
1.09 ± 0.34pmol/g tissue). The repeated (8 days) local
administration of RA, at doses able to produce marked
anti-inflammatory effects (see above), reduced the SP
content by 58% in the inflamed paw of mice (0.54 ±
0.12pmol/g tissue;  p <  0.05 as compared with the
inflamed paw treated with vehicle). Repeated topical
capsaicin administration did not significantly reduce
SP paw levels (0.73 ± 0.14pmol/g tissue).
Discussion
The  main  result  of  this  study  is  that  RA  topically
administered for 8 days exerts a marked anti-inflam-
matory effect in several models of inflammation. The
anti-inflammatory  effect  was  comparable  with  that
obtained with a 10-fold lower dose of capsaicin.
RA, when administered acutely, produced an addi-
tive inflammatory effect on carrageenan- or histamine-
induced oedema in mice or guinea-pigs, respectively,
but  at  a  variance with  capsaicin,  acute  topical  RA
administration  did  not  produce  any  nociceptive  or
hyperemic  reaction.  Capsaicin  is  known  to  induce
neurogenic inflammation (e.g. vasodilatation, protein
extravasation and oedema) through an acute release of
vasoactive  peptides,  such  as  SP,  neurokinin A  and
calcitonin gene-related peptide (CGRP) from sensory
nerve terminals.12–14 It is noteworthy that capsaicin-
induced oedema or plasma protein extravasation is
almost  completely  absent  in  genetically  tachykinin-
deficient mice.15A release of tachykinins from sensory
terminal  nerves  leading  to  an  activation  of  their
receptors present on the skin surface may explain the
acute  additive  inflammatory  effect  of  RA  in  our
experimentally induced oedemas.
Although carrageenan injection leads to the genera-
tion  of  a  range  of  inflammatory  mediators,  the
noticeable  reduction  of  paw  oedema  thickness
induced by the NK1 receptor antagonist CP 96.345 in
rats16 and the almost complete disappearance of paw
oedema in mice induced by the other NK1 receptor
antagonist  CP  122,721  (Vieira  et  al.,  unpublished
observations) support the involvement of SP in this
inflammatory oedema. Furthermore, in NK1 receptor
knockout  mice  the  carrageenan  oedema  was  sig-
nificantly reduced.17
As  concerns  the  anti-inflammatory  effect  of  RA
resulting  from an 8-day treatment, a desensitization
action on peripheral nerve endings, already described
for  capsaicin,  may  explain,  at  least  in  part, such  a
phenomenon. In keeping with the above, the noci-
ceptive reactions observed during the first days only
after  capsaicin  application  or  i.d.  injection  disap-
peared on the second or third day of treatment. It is
known that repeated exposure to capsaicin results in
a  desensitization  of  chemosensitive  sensory  affer-
ents,18 depletion of sensory peptides such as SP19,20
and  a  loss  of  local  tissue  reactions upon  chemical
irritation.20 Desensitization of a flare reaction induced
by  a  prolonged  local  exposure  to  capsaicin,  i.d.
bradykinin  and  histamine  has  been  described  in
human skin.21The anti-inflammatory effect of RA and
capsaicin found in our experimental conditions was
more  marked  towards  carrageenan  than  histamine;
different mechanisms of action of these inflammatory
agents  can  be  responsible  for  these  differences  in
desensitization.  Histamine  has  been  described  to
excite small diameter afferent neurones and evoke the
release of neuropeptides from vasoactive local nerve
endings.22 It is interesting to note that paw oedema
induced  by  histamine  was  abolished  in  capsaicin-
denervated  rats.23 Our  findings  in  the  guinea-pig
eyelid  show  that  the  histamine-induced  oedema  is
also dependent on other mediators.
On the other hand, carrageenan paw oedema was
blunted by the local application of RA or capsaicin and
it was matched by a significant reduction of SP tissue
levels at least after the local application of RA.
In contrast to what happens in acute inflammation,
in  subchronic  inflammation  induced  by  Freund’s
adjuvant, RA was barely more effective than capsaicin
in reducing oedema formation. Freund’s adjuvant is
able to produce a relatively stable inflammation that
was decreased partially by local application of RA and
was markedly affected by i.d. injection of both RA and
capsaicin. The  more  effective  counteraction  of  the
oedema induced by i.d. versus topical administration
of  both  compounds  is  probably  due  to  a  stronger
desensitization induced by this route. On the other
hand, Freund’s adjuvant-induced chronically inflamed
tissue in the rat has been reported to be associated
with changes in SP content in nerves supplying the
inflamed paws24 and systemic capsaicin administra-
tion  reduced  the  oedema  formation  concomitantly
with the reduction of SP in nerve tissues.25
The  relevance  of  the  data  presented  should  be
associated  with  the  observation  that  RA  does  not
possess the pungent and painful  effect of capsaicin
but maintains its anti-inflammatory activities. Topical
capsaicin  has  shown  therapeutic  potential  in  the
treatment  of  cutaneous  disorders  such  as  post-
herpetic neuralgia, painful diabetic neuropathy, pruri-
tus, psoriasis, post-mastectomy pain syndrome, vulvar
vestibulitis,26–29 but its utility appears to be limited
primarily  by  its  irritant  properties.  RA  has  the
potential  to  be  a  new  capsaicin-like  substance
endowed  with  anti-inflammatory  effects  on  several
models of inflammation without the pungent charac-
teristics of capsaicin.
Anti-inflammatory activity of ricinoleic acid
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